OPKO Health, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 78 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

OPKO Health, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'OPKO Health, Inc. - Product Pipeline Review - 2014', provides an overview of the OPKO Health, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of OPKO Health, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of OPKO Health, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of OPKO Health, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the OPKO Health, Inc.'s pipeline products

Reasons to buy

- Evaluate OPKO Health, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of OPKO Health, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the OPKO Health, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of OPKO Health, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of OPKO Health, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of OPKO Health, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
OPKO Health, Inc. Snapshot 7
OPKO Health, Inc. Overview 7
Key Information 7
Key Facts 7
OPKO Health, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
OPKO Health, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
OPKO Health, Inc. - Pipeline Products Glance 15
OPKO Health, Inc. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
OPKO Health, Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
OPKO Health, Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 20
OPKO Health, Inc. - Drug Profiles 21
calcifediol MR 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
fermagate 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MOD-4023 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CTAP-201 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
lunacalcipol 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SCH-900978 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MOD-5017 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MOD-9017 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
OPK-0018 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CTA-091 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drug For Atherosclerosis 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug For Rheumatoid Arthritis 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Flu Vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MOD-1001 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MOD-1002 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MOD-5014 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MOD-6030 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MOD-7023 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MOD-9013 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Oligonucleotide For Dravet Syndrome 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Oligonucleotide For MPS-1 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Oligonucleotide For Rett Syndrome 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SR-3306 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Drugs to Inhibit CYP24 for CKD and Pre-CKD 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
OPKO Health, Inc. - Pipeline Analysis 52
OPKO Health, Inc. - Pipeline Products by Target 52
OPKO Health, Inc. - Pipeline Products by Route of Administration 54
OPKO Health, Inc. - Pipeline Products by Molecule Type 55
OPKO Health, Inc. - Pipeline Products by Mechanism of Action 56
OPKO Health, Inc. - Recent Pipeline Updates 58
OPKO Health, Inc. - Dormant Projects 72
OPKO Health, Inc. - Company Statement 73
OPKO Health, Inc. - Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
OPKO Health, Inc., Key Information 7
OPKO Health, Inc., Key Facts 7
OPKO Health, Inc. - Pipeline by Indication, 2014 9
OPKO Health, Inc. - Pipeline by Stage of Development, 2014 11
OPKO Health, Inc. - Monotherapy Products in Pipeline, 2014 12
OPKO Health, Inc. - Out-Licensed Products in Pipeline, 2014 13
OPKO Health, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
OPKO Health, Inc. - Phase III, 2014 15
OPKO Health, Inc. - Phase II, 2014 16
OPKO Health, Inc. - Phase I, 2014 17
OPKO Health, Inc. - Preclinical, 2014 18
OPKO Health, Inc. - Discovery, 2014 20
OPKO Health, Inc. - Pipeline by Target, 2014 53
OPKO Health, Inc. - Pipeline by Route of Administration, 2014 54
OPKO Health, Inc. - Pipeline by Molecule Type, 2014 55
OPKO Health, Inc. - Pipeline Products by Mechanism of Action, 2014 57
OPKO Health, Inc. - Recent Pipeline Updates, 2014 58
OPKO Health, Inc. - Dormant Developmental Projects,2014 72
OPKO Health, Inc., Subsidiaries 75